Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
News about Werewolf Therapeutics, Inc. (Nasdaq: HOWL) centers on its progress in developing conditionally activated immune therapies for cancer and other immune-mediated conditions. Company announcements frequently highlight updates from its PREDATOR platform, which is used to design INDUKINE cytokine prodrugs and INDUCER T cell engager candidates that aim to stimulate adaptive and innate immunity while limiting systemic toxicity.
Investors and followers of HOWL can expect regular news on the clinical development of WTX-124 and WTX-330, Werewolf’s most advanced INDUKINE programs. Press releases describe Phase 1/1b and Phase 1b/2 trial updates in multiple advanced solid tumors, regulatory designations such as Fast Track status for WTX-124 in cutaneous melanoma after standard immunotherapy, and emerging data on tolerability, antitumor activity, and tumor-selective activation strategies.
News flow also covers the company’s expanding INDUCER T cell engager platform, including preclinical data for WTX-1011, an anti‑STEAP1 candidate for STEAP1-expressing cancers, and WTX-2022, targeting CDH6-expressing cancers. Werewolf reports on presentations at scientific and medical meetings, such as the Society for Immunotherapy of Cancer’s Annual Meeting and disease-focused summits, where it shares data on sequential dosing of IL‑12 and IL‑2 INDUKINE molecules, masking strategies to reduce cytokine release, and real-time pharmacokinetic insights.
Additional HOWL news items include quarterly financial results, business updates, conference participation, and partnering discussions around its broader INDUKINE portfolio, including WTX-712, WTX-518, and WTX-921. For readers tracking immuno-oncology developments, the Werewolf Therapeutics news page provides a consolidated view of clinical milestones, regulatory interactions, scientific presentations, and corporate strategy disclosures related to the company’s conditionally activated immune therapeutics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Werewolf Therapeutics (Nasdaq: HOWL) announced the publication of preclinical data for mWTX-330, an Interleukin-12 INDUKINE molecule, in Cancer Immunology Research. This study demonstrates that mWTX-330 effectively stimulates an anti-tumor immune response by selectively delivering IL-12 to the tumor microenvironment while minimizing systemic toxicity. Key findings include robust immune activation in multiple tumor models and improved T-cell activity without signs of exhaustion. The company is preparing for a Phase 1 clinical trial for WTX-330 in patients with advanced solid tumors or lymphoma resistant to checkpoint inhibitors. The trial aims to evaluate safety and efficacy, marking a significant step in Werewolf's mission to enhance cancer treatments through targeted immune activation.
Werewolf Therapeutics (Nasdaq: HOWL) announced significant advancements in its clinical trials and financial position. The company is preparing to release initial clinical data for its IL-2 INDUKINE WTX-124 monotherapy in Q4 2023, while the first patient has been dosed in the IL-12 INDUKINE WTX-330 trial. Furthermore, it nominated WTX-712 for preclinical development. The financial update shows a cash position of $129.3 million, with guidance extended to cover operations through Q4 2024. Collaboration revenue rose to $7.3 million in Q4 2022, a notable increase from 2021, amidst rising expenses primarily related to R&D.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the publication of abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. Key presentations include:
- Abstract 1829: Generation of IL-21 INDUKINE™ molecules for cancer treatment on April 17, 9:00 a.m. - 12:30 p.m.
- Abstract CT133: Phase 1/1b study of WTX-124, April 17, 1:30 p.m. - 5:00 p.m.
- Abstract CT254: First-in-human study of WTX-330 on April 18, 1:30 p.m. - 5:00 p.m.
Werewolf is focused on conditionally activated therapeutics to enhance the immune response against cancer.
Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced its upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled from April 14-19 in Orlando, Florida. The abstract, numbered 1829, details the generation of IL-21 INDUKINE™ molecules aimed at activating the immune system while minimizing side effects. The presentation will occur on April 17 from 9:00 a.m. to 12:30 p.m. at Poster Section 24, Board Number 1. The company utilizes its proprietary PREDATOR™ platform to develop conditionally activated therapeutics targeting solid tumors, including its lead candidates, WTX-124 and WTX-330.
Werewolf Therapeutics has initiated a Phase 1 clinical trial for WTX-330, a novel Interleukin-12 (IL-12) therapy designed for the treatment of advanced solid tumors and Non-Hodgkin lymphoma. This trial marks the second INDUKINE molecule to enter clinical evaluation from their PREDATOR protein engineering platform. Dosing the first patient highlights Werewolf's commitment to advancing cancer therapies targeting hard-to-treat tumors. WTX-330 aims to minimize off-tumor toxicities while delivering potent treatment directly to the tumor microenvironment, potentially maximizing clinical benefits.
Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced that Randi Isaacs, M.D., its Chief Medical Officer, will present at the SVB Securities Global Biopharma Conference. The virtual presentation is scheduled for February 16, 2023, at 8:40 AM ET, during the conference which runs from February 14-16. This event highlights the company's innovative PREDATOR™ platform, designed to stimulate the immune system while minimizing peripheral activity. Werewolf's leading candidates, WTX-124 and WTX-330, are conditionally activated molecules aimed at treating various solid tumors. A link to the live webcast and archived presentation will be available following the event.